Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Somatropin - Pfizer

X
Drug Profile

Somatropin - Pfizer

Alternative Names: Genotonorm; Genotropin; PN 180,307

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Department of defence; Pfizer; University of Texas Medical Branch
  • Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
  • Mechanism of Action Human growth hormone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Growth disorders; Prader-Willi syndrome; Short stature; Somatotropin deficiency; Turner's syndrome
  • Phase II/III Burns

Most Recent Events

  • 03 Apr 2014 Interim Efficacy and adverse events data from a phase IIIb trial in infants born Small for gestational age released by Pfizer
  • 30 Jun 2005 Preregistration for Turner's syndrome in USA (SC)
  • 22 Sep 2004 Somatropin (MiniQuick) has been launched in Japan in three new dosage forms
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top